The Worldwide Travel Vaccines Industry is Expected to Reach $10.7 Billion by 2027 –

The Worldwide Travel Vaccines Industry is Expected to Reach $10.7 Billion by 2027 –

The Worldwide Travel Vaccines Industry is Expected to Reach $10.7 Billion by 2027 –

DUBLIN–(BUSINESS WIRE)–The “Travel Vaccines Market Research Report by Type (Attenuated Vaccines, Conjugate Vaccines, and DNA Vaccines), Composite, Disease, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to’s offering.

The Global Travel Vaccines Market size was estimated at USD 6,097.58 million in 2021, USD 6,694.43 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.96% to reach USD 10,781.82 million by 2027.

Cumulative Impact of 2022 Russia Ukraine Conflict:

We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States.

This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Travel Vaccines market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Travel Vaccines Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report answers questions such as:

1. What is the market size and forecast of the Global Travel Vaccines Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Travel Vaccines Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Travel Vaccines Market?

4. What is the competitive strategic window for opportunities in the Global Travel Vaccines Market?

5. What are the technology trends and regulatory frameworks in the Global Travel Vaccines Market?

6. What is the market share of the leading vendors in the Global Travel Vaccines Market?

7. What modes and strategic moves are considered suitable for entering the Global Travel Vaccines Market?

Market Dynamics


  • Increasing number of international tourism
  • Rising research & development activities by key players
  • Growing development of combination vaccines


  • Higher expenditure in research & development


  • Innovations in novel vaccine technologies and tech advancements
  • Government support for development of vaccines


  • Lack of awareness amongst travellers

Companies Mentioned

  • Abbott Laboratories
  • ALK-Abello A/S
  • Altimmune, Inc
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bavarian Nordic A/S
  • Baxter International Inc
  • Cadila Healthcare Limited
  • CSL Limited
  • Dynavax Technologies
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering Inc.
  • Janssen Vaccines (Subsidiary of Johnson & Johnson)
  • Medimmune LLC
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A
  • Serum Institute of India
  • Shenzhen Kangtai biological products Limited
  • SK Chemicals
  • Takeda Pharmaceuticals U.S.A., Inc.
  • Valneva SE

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900